Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

Related Articles by Review for PubMed (Select 21029821)

1.

Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).

Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS, Jones-Burton C, Tershakovec AM.

Am J Cardiol. 2010 Nov 1;106(9):1255-63. doi: 10.1016/j.amjcard.2010.06.051.

PMID:
21029821
2.

[Ezetimibe: from pharmacology to clinical trials].

Tellier P.

Ann Endocrinol (Paris). 2003 Dec;64(6):442-7. Review. French.

PMID:
15067249
3.

Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.

Robinson JG, Davidson MH.

Expert Rev Cardiovasc Ther. 2006 Jul;4(4):461-76. Review. Erratum in: Expert Rev Cardiovasc Ther. 2006 Sep;4(5):772.

PMID:
16918265
4.

Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis.

Mikhailidis DP, Lawson RW, McCormick AL, Sibbring GC, Tershakovec AM, Davies GM, Tunceli K.

Curr Med Res Opin. 2011 Jun;27(6):1191-210. doi: 10.1185/03007995.2011.571239. Epub 2011 Apr 7. Review.

PMID:
21473671
5.
6.

Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.

Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM.

Atherosclerosis. 2012 Aug;223(2):251-61. doi: 10.1016/j.atherosclerosis.2012.02.016. Epub 2012 Feb 16. Review.

PMID:
22410123
7.

The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?

Doggrell SA.

Expert Opin Pharmacother. 2012 Jul;13(10):1469-80. doi: 10.1517/14656566.2012.696098. Review.

PMID:
22725704
8.

Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia.

Lyseng-Williamson KA.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):49-56. doi: 10.2165/11209150-000000000-00000. Review.

PMID:
22208355
9.

Intestinal sterol transporters and cholesterol absorption inhibition.

Davis HR Jr, Tershakovec AM, Tomassini JE, Musliner T.

Curr Opin Lipidol. 2011 Dec;22(6):467-78. doi: 10.1097/MOL.0b013e32834c7c28. Review.

PMID:
22101558
10.

Lipid-lowering effects of ezetimibe and simvastatin in combination.

Ijioma N, Robinson JG.

Expert Rev Cardiovasc Ther. 2011 Feb;9(2):131-45. doi: 10.1586/erc.10.179. Review.

PMID:
21453210
11.

Pitavastatin - results from phase III & IV.

Betteridge J.

Atheroscler Suppl. 2010 Dec;11(3):8-14. doi: 10.1016/S1567-5688(10)71064-3. Review.

PMID:
21193153
12.
13.

[Lipid therapy in daily routine].

Sonntag F, Schaefer JR, Gitt AK, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K.

Dtsch Med Wochenschr. 2012 Oct;137(40):2047-52. Epub 2012 Sep 28. Review. German.

PMID:
23023622
14.

Liptruzet: a combination of ezetimibe and atorvastatin.

[No authors listed]

Med Lett Drugs Ther. 2013 Jun 24;55(1419):49-50. Review. No abstract available.

PMID:
23797796
15.

[An inhibitor of intestinal cholesterol transporter].

Sano M.

Nihon Rinsho. 2013 Sep;71(9):1661-6. Review. Japanese.

PMID:
24205731
16.

Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.

Ahmed MH, Byrne CD.

Diabetes Obes Metab. 2010 Nov;12(11):958-66. doi: 10.1111/j.1463-1326.2010.01261.x. Review.

PMID:
20880342
17.

Ezetimibe therapy: mechanism of action and clinical update.

Phan BA, Dayspring TD, Toth PP.

Vasc Health Risk Manag. 2012;8:415-27. doi: 10.2147/VHRM.S33664. Epub 2012 Jul 3. Review.

18.

Effects of ezetimibe on atherosclerosis in preclinical models.

Davis HR Jr, Lowe RS, Neff DR.

Atherosclerosis. 2011 Apr;215(2):266-78. doi: 10.1016/j.atherosclerosis.2011.02.010. Epub 2011 Feb 17. Review.

PMID:
21397230
19.

Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update.

Musso G, Cassader M, Gambino R.

Curr Opin Lipidol. 2011 Dec;22(6):489-96. doi: 10.1097/MOL.0b013e32834c37ee. Review.

PMID:
21986643
20.

Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe?

Green D, Panayotova R, Ritchie JP, O'Riordan E, McDonald J.

J Ren Care. 2012 Sep;38(3):138-46. doi: 10.1111/j.1755-6686.2012.00309.x. Epub 2012 May 22. Review.

PMID:
22613701
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk